Clene Nanomedicine Announces Over 50% of Subjects Randomized in RESCUE-ALS Clinical Trial for Treatment of Amyotrophic Lateral Sclerosis (ALS) with Lead Nanocatalytic Therapeutic\, CNM-Au8